Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

Genetics, Family History, and Lung Cancer
Author
Howard (Jack) West, MD

Many members have asked questions about increased risk of lung cancer among family members of people who have developed lung cancer. Overall, I have not highlighted this, partly because we don't tend to highlight genetics as a major contributor of lung cancer risk. But the fact is that 10-15% of people who develop lung cancer never smoked, and the vast majority of smokers never develop lung cancer. And we see that the never-smoker population with lung cancer is disproportionately female (as covered in a prior post), and that multiple surgical series of show much higher proportions of never-smokers with lung cancer in studies from China (57% never-smokers in article here), and Japan (48% never-smokers in article here). Genetics must be an important modifier, since some people chain smoke for decades without developing lung cancer, while others can develop lung cancer with no obvious risk factors.

First, there have been family clusters of lung cancer described in reports for several decades (abstract here). Since then, many reports have come out that suggest an increased risk of developing lung cancer for people with first-degree relatives with lung cancer (article here; abstract here). This appears to be independent of smoking exposure, which often overlaps with familial genetic traits. However, the familial genetic risk appears to be greatest among family members of never-smokers and those with adenocarcinomas (article here; another article here). There are many studies out there with a wide range of methods to assess risk, in a wide range of populations. Taken together, many of the studies in smokers show an increased risk in the 30-50% range, and the risk for relatives of never-smokers with lung cancer may be in the range of 6x normal. But it's important to consider that the risk of developing lung cancer for an individual person is still low, so it doesn't mean that a family member of someone with lung cancer is likely to get it as well.

What can we do with this information? Of course, if we could learn more about preventive approaches that may be effective, whether supplements or other interventions, we could target higher risk ppopulations for treatments to reduce risk. Unfortunately, we haven't identified any such approaches yet. There are a few screening studies that are enrolling people who may or may not have smoked but have a family history of lung cancer, so this designates them as higher risk even without the smoking history we're usually focusing on to estimate increased risk for smoking. But smoking status is still a very dominant factor, so my assessment would be that the most important point to take away from the increased risk of lung cancer among immediate family members of people with lung cancer is to reduce the risk by not smoking. If risk is going to be elevated, better to have that increase be for a very, very slight baseline risk. We can't control genetics, so most of what we can do is reduce the risks associated with behaviors that can be modified.

Next Previous link

Previous PostNext Post

Related Content

Article
Advance directives are a powerful way to take control of healthcare choices. These documents allow you to outline preferences for medical care and specify end-of-life wishes. These documents can also be a way to appoint loved ones who you would like to help with these decisions, such as a healthcare proxy (someone to make decisions on your behalf, if you cannot). As cancer treatments can involve aggressive treatments and/or complex medical management, having advance directives ensures that your desires regarding treatment options and end-of-life care are clearly communicated. 
Image
2024-25 patient perspectives header
Article
Tell your story and help us help others! Apply online now for this paid opportunity. This program gives a voice to those who have experience in participating in a clinical trial for a cancer diagnosis. Your voice helps to educate and advocate for others who are in or who may be considering a clinical trial.  We want to hear from you!
Image
Foro de Pacientes de Terapias Dirigidas de Cáncer de Pulmón
Video
¡El vídeo completo bajo demanda está disponible para verlo!

Forum Discussions

Hi elysianfields and welcome to Grace.  I'm sorry to hear about your father's progression. 

 

Unfortunately, lepto remains a difficult area to treat.  Recently FDA approved the combo Lazertinib and Amivantamab...

Hello Janine, thank you for your reply.

Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...

Hi elysianfields,

 

That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...

Hello Linda, my name is Alexandra Beneke, I'm the Outreach Manager for GRACE. Your willingness to share your experiences and knowledge with the cancer community is truly inspiring. Your dedication to...

Recent Comments

JOIN THE CONVERSATION
I could not find any info on…
By JanineT GRACE … on
Hi elysianfields,

 

That's…
By JanineT GRACE … on
Hello Janine, thank you for…
By elysianfields on
EGFR
By happybluesun on